research Re: Effect of 5α-Reductase Inhibitors on Sexual Function: A Meta-Analysis and Systematic Review of Randomized Controlled Trials
5α-Reductase inhibitors can negatively impact sexual function.
Search
for
Sort by
Research
510-540 / 1000+ results 
research Tamoxifen for flutamide/finasteride-induced gynecomastia
Tamoxifen effectively treats gynecomastia without causing impotence.
research Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia.
Dutasteride may lower the chance of finding prostate cancer in men with enlarged prostates.
research Real-world assessment of ritlecitinib in patients with severe alopecia areata: a 24-week multicentre retrospective study
Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.
research C36 LONG TERM TREATMENT WITH FINASTERIDE IN MEN WITH LUTS - A 13 YEARS FOLLOW UP
research Topic use of dutasteride for treatment of androgenic alopecia in male and female: A controlled pilot study
Dutasteride can help treat hair loss in both men and women.
research ADVERSE EFFECTS OF RITLECITINIB IN ADULTS AND ADOLESCENTS WITH ALOPECIA AREATA: A LITERATURE REVIEW
Ritlecitinib is generally safe for long-term use, with mostly mild side effects.
research Tofacitinib in the Management of Alopecia Universalis
Tofacitinib helped a woman regrow hair with no major side effects.
research A retrospective study of oral tofacitinib therapy for alopecia areata
research Pharmacological inhibition of 5α-reductase in androgenetic alopecia: a comparative narrative review of finasteride and dutasteride, with attention to responder heterogeneity and female pattern hair loss
Finasteride and dutasteride are the most evidence-supported pharmacological treatments for androgenetic alopecia (AGA) in both men and women. Finasteride 1 mg/day reduces serum DHT by about 70%, while dutasteride 0.5 mg/day achieves approximately 90% suppression, with dutasteride showing slightly greater hair count gains. A pivotal trial found dutasteride 2.5 mg superior to finasteride 5 mg/day, but the 0.5 mg dose is standard due to its efficacy and lower systemic exposure. Genetic factors, particularly androgen receptor variations, significantly influence treatment response. In women, higher doses of finasteride and variable doses of dutasteride are effective, especially in postmenopausal and some premenopausal groups. The choice between these drugs involves balancing DHT suppression, drug half-life, and tolerability, with genetic modifiers being an important area for future research.
research Pharmacological inhibition of 5α-reductase in androgenetic alopecia: a comparative narrative review of finasteride and dutasteride, with attention to responder heterogeneity and female pattern hair loss
Finasteride and dutasteride are the most evidence-supported pharmacological treatments for androgenetic alopecia (AGA) in both men and women. Finasteride 1 mg/day reduces serum DHT by about 70%, while dutasteride 0.5 mg/day achieves approximately 90% suppression, with dutasteride showing slightly greater hair count gains. A pivotal trial found dutasteride 2.5 mg superior to finasteride 5 mg/day, but the 0.5 mg dose is standard due to its efficacy and lower systemic exposure. Genetic factors, particularly androgen receptor variations, significantly influence treatment response. In women, higher doses of finasteride and variable doses of dutasteride are effective, especially in postmenopausal and some premenopausal groups. The choice between these drugs involves balancing DHT suppression, drug half-life, and tolerability, with genetic modifiers being an important area for future research.
research Serenoa repens induced erectile dysfunction: Underdiagnosis and phytovigilance
Saw palmetto may cause erectile dysfunction and needs better safety monitoring.
research Medications Most Commonly Associated With Erectile Dysfunction: Evaluation of the Food and Drug Administration National Pharmacovigilance Database
Certain medications, especially 5-α reductase inhibitors and neuropsychiatric drugs, are often linked to erectile dysfunction.
research 331 An open label clinical trial of the JAK inhibitor tofacitinib for alopecia areata
Tofacitinib helped over half of the patients with severe hair loss regrow at least 50% of their hair.
research FRI-02 FROM GIRLS TO BOYS TO OLDER MEN, THE INTERESTING TALE OF THE GUEVEDOCES AND 5-ALPHA REDUCTASE INHIBITORS
The discovery of 5α-reductase deficiency in guevedoces led to the development of important urologic medications.
research Associations between semen quality and lower urinary tract symptoms in ageing male
The conclusion is that doctors should be careful when prescribing 5α-reductase inhibitors due to possible serious side effects, and they should discuss these risks with patients.
research Ability to cycle despite severe freezing of gait in atypical parkinsonism in Fahr's syndrome
Finasteride significantly reduced tics and obsessive-compulsive symptoms in Tourette syndrome patients.
research ANAIS DO I CONGRESSO MÉDICO DE FORMOSA - COMEF
Dutasteride is more effective and better tolerated than finasteride for hair loss treatment.
research An overview on 5α-reductase inhibitors
5α-reductase inhibitors, like Finasteride and Dutasteride, help manage benign prostatic hyperplasia.
research Efficacy and Safety of Low-Dose (0.2 mg) Dutasteride for Male Androgenic Alopecia: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase III Clinical Trial
Low-dose dutasteride effectively and safely promotes hair growth in men.
research Adverse Sexual Effects of Treatment with Finasteride or Dutasteride for Male Androgenetic Alopecia: A Systematic Review and Meta-analysis
Finasteride and dutasteride increase sexual dysfunction risk by 1.57 times in male hair loss treatment.
research Dutasteride
Dutasteride may become the top choice for treating hair loss.
research TOFACITINIB IN OVERLAPPING AUTOIMMUNE AND AUTOINFLAMMATORY DISORDERS: A CASE REPORT OF A DUAL GRAHAM-LITTLE-PICCARDI-LASSEUR SYNDROME AND HIDRADENITIS SUPPURATIVA
Tofacitinib effectively treated a woman's complex autoimmune and autoinflammatory disorders.
research Combined Sabal and Urtica extract vs finasteride in BPH (Alken stage I–II)
Sabal and Urtica extract works as well as finasteride for treating BPH, with fewer side effects.
research Efficacy of Oral Tofacitinib in Alopecia Areata, Alopecia Totalis, and Alopecia Universalis
Tofacitinib significantly regrows hair in severe alopecia without major side effects.
research Oral finasteride use and sexual adverse events: signal detection from disproportionality analyses of data from the United States Food and Drug Administration Adverse Event Reporting System
Oral finasteride may cause more sexual side effects than expected, possibly due to negative publicity and reporting bias.
research PROSPECTIVE EVALUATION ON SEXUAL DYSFUNCTION PERSISTENCE, WORSENING OR IMPROVEMENT IN BPH PATIENTS AFTER FINASTERIDE OR DUTASTERIDE TREATMENT
Finasteride and dutasteride can affect sexual function in BPH patients.
research Finasteride
research Tofacitinib Loaded Squalenyl Nanoparticles for Targeted Follicular Delivery in Inflammatory Skin Diseases
Tofacitinib nanoparticles can safely and effectively treat alopecia areata by targeting hair follicles.
research A Case of Tofacitinib for the Treatment of Resistant Vitiligo and Sustained Repigmentation After Discontinuation
A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.